Since Monday, the agenda of Patrick Alexandre, president of Crossject, a Dijon biotechnology company behind the highly innovative Zeneo needle-free injection device, has been extremely busy. After more than a year of procedure, he learned a few days ago that his company had been selected following the call for tenders launched by Barda (Biomedical Advanced Research and Development Authority), as we announced, within the framework of a first delivery of Zeneo Midazolam intended for the national strategic stock* of the United States.
During a telephone interview, Patrick Alexandre confirms that the signing of the first contract for 60 million dollars took place on Friday, June 17. And to specify: “The contract concerns a product that we are developing in Europe for the treatment of severe epilepsies and for which we have a German customer. This signature therefore represents a real opportunity for us in America. Beyond that, the advantage is…
